BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AGAH - ECPv5.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGAH
X-ORIGINAL-URL:https://dev.agah.eu
X-WR-CALDESC:Events for AGAH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20030330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20031026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20030223
DTEND;VALUE=DATE:20030226
DTSTAMP:20260929T023029
CREATED:20190315T014006Z
LAST-MODIFIED:20190613T203000Z
UID:3118-1045958400-1046217599@dev.agah.eu
SUMMARY:12th AGAH Annual Meeting 2003
DESCRIPTION:  \nBack to the Future – Upgrading classical test strategies for innovative drugs\n\n\n\n	Announcement \n\n\n\nFebruary 23 – 25\, 2003\, Bonn\, Germany\nWorkshops and sessions during the pre-symposium day concentrated on medical and report writing\, the FDA guidelines referring to time-series data\, the Declaration of Helsinki and the European directives regulating the conduct of clinical trials. Symposium and Poster sessions focussed on current regulatory and socio-economical aspects of drug development and their perspectives\, the evolution of clinical trial methods\, especially in the development of anti-cancer\, anti-inflammatory\, anti-neurodegenerative and genetically engineered drugs. \n\n\n\n\n\n\n\n	Presentations of the Annual Meeting 2003 \n\nSession I: Today's Setting of Drug Development\n\n\n\nR. Shah\, London\n\n\nRisk-benefit Evaluation in Approval of traditional and innovative Drugs (Abstract)\nNo presentation available \n\n\n\n\nM. Holz-Slomczyk\, BfArM\, Bonn\n\n\nGuidelines for Drug Approval – Today and Tomorrow (Abstract)\nNo presentation available \n\n\nSession II: Socioeconomic acpects of new Drugs\n\nWorkshop on the German Medicinal Act (AMG) – Presentations\n\nM. Schlander\, Witten-Herdecke\nWhat-does-the-society-want-Schlander_01\nWhat does the society want? \n\n\nJ. Göben\, BfArM\, Bonn\n\n\nWhat can the Society afford? (Abstract)\nNo presentation available \n\n\nSession III: Essential Tools – Today and Tomorrow\n\n\nB. Meibohm\, Memphis\n\n\nExposure/Response vs. Dose/Response Relationship in Drug Development (Abstract)\nNo presentation available \n\n\n\nE. Wingender\, Göttingen\n\n\nUsing Bioinformatics for bridging the Genotype-Phenotype Gap (Abstract)\nNo presentation available \n\n\nSession IV: Development of Anticancer Drugs\n\nB. Osterwalder\, Basel\n\nXeloda\, an old cytotoxic in a new Form: new Development Paradigm required? (Abstract)\nNo presentation available \n\n\n\nD. Voliotis\, Wuppertal\n\n\nSafety\, Toxicity and Efficacy of Antineoplastic Compounds – a clinical View (Abstract)\nNo presentation available \n\n\n\nD. Laurent\, Berlin\n\n\nDesign and Evaluation of clinical Studies with Angiogenesis Inhibitors (Abstract)\nNo presentation available \n\n  \n\n\n\nSession V: Development of Anti-inflammatory Drugs\n\n\n\n\n\nK. Brune\, Erlangen-Nürnberg\n\n\nMethods to assess the Safety and Efficacy of traditional Compounds (NSAID\, Steroids) [Abstract]\nNo presentation available \n\n\n\n\n\n\nM. F. Neurath\, Mainz\n\n\nInflammatory Bowel Disease: Cytokines and Cytokine Therapies (Abstract)\nNo presentation available \n\n\n\n\n\nSession VI: Development of Anti-Neurodegenerative Drugs\n\n\n\n\n\nC. Gilles\, Rouffach\, France\n\n\nFunctional MRI in neurodegenerative Disease (Abstract)\nNo presentation available \n\n\n\n\n\n\nA. Lammertsma\, Amsterdam\n\n\nPotential use of PET in Drug Development: labelled Drugs\, functional Changes (e.g. Flow and Metabolism)\, Receptor Occupancy\, Dose Response Curves (Abstract)\nNo presentation available \n\n\n\n\n\nSession VII: Development of genetically engineered Drugs\n\n\n\n\nU. Keilholz\, Berlin\n\n\nGene- and Immunotherapy in Oncology: Study Concepts\, Endpoints and first Results (Abstract)\nNo presentation available \n\n\n\n\n\nV. Kessler\, Freiburg\n\n\nTissue Engineering (Abstract)\nNo presentation available \n\n\n\n\n\nF. Jakob\, Würzburg\n\n\nStem Cell Therapy (Abstract)\nNo presentation available \n\n\n\n\nWorkshops\n\n\n\n\nR. Hermann\, Frankfurt\, W. Haverkamp\, Berlin\, U. Bischoff\, Hamburg\n\n\nQTc – „Time series data“ (Abstract)\nNo presentation available \n\n\n\n\n\nK. Breithaupt-Grögler\, Frankfurt and B. Hughes-Formella\, Hamburg\n\n\nMedical Writing – Report Writing (Abstract)\nNo presentation available \n\n\n\n\n\n\nT. Sudhop\, Bonn\n\n\n\n\n\n\nK. Olejniczak\, BfArM\, Bonn\n\n\nPreclinical requirements to studies in children (Abstract)\nNo presentation available
URL:https://dev.agah.eu/event/12th-agah-annual-meeting-2003/
LOCATION:Annual Meeting 2003\, Bonn\, Deutschland
CATEGORIES:Annual Meetings
END:VEVENT
END:VCALENDAR